10
Participants
Start Date
June 21, 2023
Primary Completion Date
June 30, 2025
Study Completion Date
June 30, 2025
Combination of Tumor-infiltrating lymphocyte transfer with ANV419
"The study uses a personalized IMP (investigational medicinal product), i.e. TIL product in combination with ANV419.~Day 0: Autologous TIL: (minimum 5 x 10\^9 and up to 2x 10\^11 lymphocytes) administered intravenously over 20 to 30 minutes.~Day 0: Intravenous treatment with ANV419 at 243 μg/kg 2 hours after the TIL infusion. Actual body weight will be used to calculate the dose of ANV419.~Day14: Intravenous treatment with ANV419 at 243 μg/kg. Actual body weight will be used to calculate the dose of ANV419."
RECRUITING
University Hospital Basel, Basel
Collaborators (1)
Anaveon AG
INDUSTRY
University Hospital, Basel, Switzerland
OTHER